LYEL News and Press, Lyell Immunopharma Inc. From 05/05/25

National Health Investors Inc. (NHI) is expected to report $1.13 for Q1 2025 Palomar Holdings Inc. (PLMR) is expected to report $1.45 for Q1 2025 Weave Communications Inc. (WEAV) is expected to report $-0.11 for Q1 2025 First National Bank Alaska (FBAK) is expected to report for Q1 20...

2025-05-04 18:48:27 ET Lyell Immunopharma, Inc. (LYEL) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 3.65%. The average open to low on the day of earnings was -5.15%. The average open ...

2025-05-04 18:43:28 ET Lyell Immunopharma, Inc. (LYEL) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in LYEL stock price following earnings has averaged ±1.23% , with a median of 1.11%....

SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced that an abstract highlighting new clinical data from the Phase 1/2...

2025-04-15 11:02:41 ET More on Lyell Immunopharma Seeking Alpha’s Quant Rating on Lyell Immunopharma Historical earnings data for Lyell Immunopharma Financial information for Lyell Immunopharma Read the full article on Seeking Alpha For further...

RMAT designation was granted based on promising clinical data from the ongoing Phase 1/2 trial of LYL314 in patients with relapsed and/or refractory large B-cell lymphoma. RMAT designation recognizes the potential of LYL314 to address significant unmet needs of patients with relapsed and/or r...

Portage Biotech Inc. (PRTG) is expected to report for Q3 2025 Aimei Health Technology Co. Ltd (AFJK) is expected to report for quarter end 2024-12-31 Generation Bio Co. (GBIO) is expected to report $-0.28 for Q4 2024 TAT Technologies Ltd. (TATT) is expected to report for quarter end 2...

Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate for the treatment of aggressive large B-cell lymphoma (LBCL) Presented positive initial data from Phase 1 multi-center clinical trial ...

Kodiak Gas Services Inc. (KGS) is expected to report $0.26 for Q4 2024 Kronos Worldwide Inc (KRO) is expected to report $0.11 for Q4 2024 Neonode Inc. (NEON) is expected to report for Q4 2024 Applied Therapeutics Inc. (APLT) is expected to report $-0.18 for Q4 2024 Churchill Capit...

XPEL Inc. (XPEL) is expected to report $0.41 for Q4 2024 MGP Ingredients Inc. (MGPI) is expected to report $1.49 for Q4 2024 Kratos Defense & Security Solutions Inc. (KTOS) is expected to report $0.05 for Q4 2024 Albany International Corporation (AIN) is expected to report $0.65 f...